PLEKHA5 as a Biomarker and Potential Mediator of Melanoma Brain Metastasis
- 30 April 2015
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 21 (9), 2138-2147
- https://doi.org/10.1158/1078-0432.ccr-14-0861
Abstract
Purpose: Approximately 40% of patients with metastatic melanoma develop brain metastases. Our purpose was to identify genes aberrantly expressed in melanoma that might be associated with propensity for brain homing. Experimental Design: We studied gene expression profiles in a cell line model of brain metastasis (cerebrotropic A375Br cells vs. parental A375P cells) and compared them with profiles of patients who developed early brain metastases and who did not. A tissue microarray containing 169 metastatic melanoma cases with variable time to brain metastasis was constructed to further study marker expression by quantitative immunofluorescence. An in vitro model of the blood brain barrier (BBB) was generated to evaluate potential mediators of brain metastases. Results: PLEKHA5 was differentially expressed in both the A375 cell line model and patient samples subjected to gene expression profiling. At the protein level, by quantitative immunofluorescence, PLEKHA5 was associated with decreased brain metastasis-free survival. PLEKHA5 overexpression was not associated with other metastatic sites. Knockdown of PLEKHA5 decreases the viability of A375Br cells, inhibits BBB transmigration and invasion in vitro. Similar results were found with YUMUL cells, cultured from a patient with overwhelming brain metastases. PLEKHA5 knockdown did not affect the viability of A375P cells. Conclusions: PLEKHA5 expression in melanoma tumors was associated with early development of brain metastases. Inhibition of PLEKHA5 might decrease passage across the BBB and decrease proliferation and survival of melanoma cells both in the brain and in extracerebral sites. Clin Cancer Res; 21(9); 2138–47. ©2014 AACR. See related commentary by Eisele et al., p. 1978Keywords
Other Versions
This publication has 52 references indexed in Scilit:
- PI3K and STAT3: A New AllianceCancer Discovery, 2011
- Melanoma Brain Metastases: Is It Time to Reassess the Bias?Current Problems in Cancer, 2011
- Dopaminergic pathway reconstruction by Akt/Rheb‐induced axon regenerationAnnals of Neurology, 2011
- Interaction between lung cancer cells and astrocytes via specific inflammatory cytokines in the microenvironment of brain metastasisClinical & Experimental Metastasis, 2010
- Molecular Pharmacology and Antitumor Activity of PHT-427, a Novel Akt/Phosphatidylinositide-Dependent Protein Kinase 1 Pleckstrin Homology Domain InhibitorMolecular Cancer Therapeutics, 2010
- Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic MelanomaClinical Cancer Research, 2009
- Genes that mediate breast cancer metastasis to the brainNature, 2009
- Rheb and mTOR Regulate Neuronal Polarity through Rap1BPublished by Elsevier BV ,2008
- Animals lacking endothelin‐converting enzyme‐2 are deficient in learning and memoryGenes, Brain and Behavior, 2007
- Akt Phosphorylates Connexin43 on Ser373, a “Mode-1” Binding Site for 14-3-3Cell Communication & Adhesion, 2007